Takeaway

• 6 years of aromatase inhibitor therapy is no more effective than 3 years in postmenopausal women who had previously received 2-3 years of tamoxifen for hormone receptor-positive breast cancer, suggests the 10-year results of the DATA trial of sequential endocrine therapy.
• Findings by Dutch investigators appear in The Lancet ...